

NIAID resources to support Zika product development

March 28, 2016

Cristina Cassetti, Ph.D.

Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
ccassetti@niaid.nih.gov



National Institute of
Allergy and
Infectious Diseases

Ongoing Zika research efforts at NIAID

- Basic research
 - Reagents (mAb panels, rec. proteins, cDNA clones)
 - BEI and WRCEVA repositories
 - Structural biology
 - Sequencing and OMICs
 - Animal models of infection and disease
 - Immune responses
 - Viral replication/evolution
 - Vector competence
- Natural history studies (Brazil, Nicaragua)
- Product development
 - Vaccines
 - Diagnostics
 - Therapeutics
 - Vector Control

NIH funding announcements

- Notices highlighting High-Priority Zika virus Research Areas
 - NOT-AI-16-026: Notice of NIAID's Interest to Highlight High-Priority Zika virus (ZIKV) Research Areas
 - NOT-HD-16-004: Notice of NICHD, NINDS, NIDCR and NIAID's Interest to Prioritize Zika Virus (ZIKV) Research Areas
- Funding Opportunity Announcement
 - PAR-16-106: Rapid Assessment of Zika Virus (ZIKV) Complications (R21). Expedited (rapid) funding mechanism for research on Zika virus (ZIKV) and its complications.

NIAID Partnerships Program for Translational Research

FY2017 Request for Applications (RFA):

Partnerships for Countermeasures against Select Pathogens (R01)


- RFA-AI-16-034
- Support for preclinical development of candidate countermeasures and related platform technologies
- Applications due date: October 3, 2016
- Performance-based, milestone-driven funding
- Up to \$750K/year (Direct Costs) for up to 5 years
- Supported Zika countermeasures
 - Therapeutics
 - Vaccines
 - Diagnostics

Pre-clinical Product Development Services


Therapeutics

Vaccines


In Vitro Assessment of Antimicrobial Activity



Interventional Agents Biopharmaceutical Products





ADM



Chemistry, Manufacturing, and Controls (CMC) Documentation for IND

Testing




Manufacturing



Animal Models



NIH's Network of Vaccine and Treatment Evaluation Units (VTEUs)



- Established in 1962
- Clinical trials for vaccines, therapeutics, and devices
- Access to diverse population types (e.g., pediatric, elderly, infected individuals)
- Expanded scope:
 - International trials
 - Epidemiologic and sample collection studies